Date: 2016-11-04
Type of information: Fundraising
Company: Plasticell (UK)
Investors:
Amount: £1.32 million (€1.48 million)
Funding type: financing round
Planned used:
- Plasticell is a biotechnology company specialising in cell and gene therapy research. The company is using massively parallel screening technologies to optimise high value cell therapies derived from stem cells. Its platform technology, CombiCult® can be applied to any cell culture process, including biopharmaceutical production, as well as cell and gene therapy manufacturing. The lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood.
- The investment will provide capital to progress the company’s therapeutic programmes, including the expansion of hematopoietic stem cells and in vitro manufacturing of blood products such as platelets, red blood cells and cancer immunotherapies.
Others: • On November 4, 2016, Plasticell announced the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors. Last year the company received a grant of approximately £1.3 million from Innovate UK to develop GMP manufacturing for hematopoietic stem cells derived from bone marrow and cord blood in collaboration with the University of Oxford and the Cell and Gene Therapy Catapult over three-years.
Therapeutic area: Cancer - Oncology
Is general: Yes
